ALT
Altimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.42
+5.88%Aug 13, 2026, 07:34 UTC
Dimensional Fund Advisors LP increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares, as disclosed in a Form 13F filing with the SEC.
Source:Aug 12, 2026, 18:37 UTC
Altimmune, Inc. held its Q2 2026 earnings call on August 12, 2026, to discuss financial results and business updates.
Source:Aug 12, 2026, 11:30 UTC
Altimmune initiated the global PERFORMA Phase 3 trial in MASH, reported positive topline data from the RECLAIM Phase 2 trial in AUD, and completed patient enrollment in the RESTORE Phase 2 trial in ALD.
Source:Aug 3, 2026, 12:00 UTC
Altimmune initiated the PERFORMA Phase 3 trial of pemvidutide in patients with MASH, a global registrational study evaluating fibrosis improvement, MASH resolution, and clinical outcomes.
Jul 28, 2026, 11:00 UTC
Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder.